张炜.中国人群中弥漫性大B细胞淋巴瘤基于基因变异的分型及其预后意义[J].内科急危重症杂志,2022,28(3):186-190
扫码阅读全文
|
| DOI：10.11768/nkjwzzzz20220303 |
| 中文关键词: 弥漫性大B细胞淋巴瘤 突变 基因分型 预后 |
| 英文关键词: |
| 基金项目:国家自然科学基金面上项目（No：81770211） |
|
| 摘要点击次数: 1852 |
| 全文下载次数: 3554 |
| 中文摘要: |
| 目的：探讨中国弥漫性大B细胞淋巴瘤（DLBCL）不同基因分型的患者在基因变异谱系上的特点及其预后差异。方法：收集187例初治非特指型DLBCL患者，行淋巴瘤相关的高通量测序及免疫荧光原位杂交检测，根据基因变异结果进行基因分型，同时收集临床资料进行分析。结果：不同基因分型DLBCL在基因变异谱系上具有较大异质性，其中EZB亚型治疗效果较好，而A53、N1、MCD亚型治疗效果较差。预后方面ST2、EZB亚型患者总体生存期显著优于N1、A53亚型。结论：不同DLBCL基因分型患者的化疗反应、总体生存期具有显著差异。DLBCL基因分型对中国患者的治疗决策及预后评估有重大意义。 |
| 英文摘要: |
| Objective: To study the mutation pattern and prognosis of different genetic subtype of diffuse large B-cell lymphoma (DLBCL) in Chinese population. Method: A total of 187 DLBCL cases in our hospital were retrospectively collected. Lymphoma-associated targeted next-generation sequencing and fluorescence in situ hybridization study were performed and genetic subtypes were determined by the mutation pattern for each sample. The relations between genetic subtype and clinical features were further analyzed. Results: Different genetic subtypes of DLBCL demonstrated heterogeneity in genetic aberrations. Patients in EZB subgroup had more favorable response to current standard R-CHOP regimen chemotherapy than in other subgroups.On the contrary, patients in A53/N1/MCD subgroup had a poor response to the treatment. Patients in ST2/EZB subgroup had a significant longer overall survival than patients in N1/A53 subgroup. Conclusion: Different genetic subtypes resulted in different treatment response and overall survival. Genetic subtype is of great significance in the treatment decision and prognosis evaluation of DLBCL in Chinese population. |
|
